NATIONAL GENE VECTOR LABORATORIES 

NIH GUIDE, Volume 25, Number 4, February 16, 1996

 

P.T. 34



Keywords:

  Genetics 

  Biological Resources 

  Gene Therapy+ 

 

National Center for Research Resources

National Cancer Institute

National Heart, Lung, and Blood Institute

National Institute of Diabetes and Digestive and Kidney Diseases

 

The National Gene Vector Laboratories (NGVLs) provide shared

resources to facilitate production of clinical grade vectors for

human gene therapy research.  The overall goals are to produce

selected vectors and distribute them to qualified clinical

investigators to conduct experimental gene therapy protocols for a

wide variety of medical conditions.

 

The NGVLs are now soliciting applications for production of clinical

grade vectors.  Priority for vector production by these facilities

will be given to protocols that have received peer-reviewed grant

support.  These vectors must have completed preclinical testing.

Preference will be given to NIH-sponsored research.

 

Specifically, the NGVLs support biomedical research by providing

investigators with the following customized services:

 

PRODUCTION

 

o  After competitive review and approval, adenoviral, retroviral and

nonviral vectors will be produced under Good Manufacturing Practices

(GMP) conditions using either investigator- or NGVL-generated vector-

producing cell lines or plasmids.

 

o  Vector batches will be documented to be free of adventitious

viruses, bacteria and replication competent viruses.

 

DISTRIBUTION

 

o  The clinical grade vectors will be distributed in quantities

adequate for use in Phase I or II clinical trials to investigators

whose clinical protocols have successfully completed competitive

review by both the NGVL Scientific Review Board and Steering

Committee.

 

APPLICATION PROCEDURE

 

o  Interested investigators may contact Dr. Kenneth Cornetta (see

INQUIRIES) to obtain application packages.

o  Applications will be reviewed by the NGVL Scientific Review Board

and by the NGVL Steering Committee.

o  The application receipt dates for 1996 are April 16 and September

3.  Thereafter, applications will be received annually in September.

 

INQUIRIES

 

Direct requests for applications and resource inquiries to:

 

Kenneth Cornetta, M.D.

Division of Hematology, Oncology

Indiana University School of Medicine

875 W. Walnut Street, Room 442

Indianapolis, IN  46202-5121

Telephone:  (317) 274-0843

FAX:  (317) 274-4243

Email:  Ken_Cornetta@iucc.iupui.edu

 

Direct programmatic inquiries regarding this research resource to:

 

Richard A. Knazek, M.D.

Clinical Research

National Center for Research Resources

6705 Rockledge Drive, Room 6128, MSC 7965

Bethesda, MD  20892-7965

Telephone:  (301) 435-0792

FAX:  (301) 480-3661

Email:  RichardK@ep.ncrr.nih.gov

 

The NGVLs are supported by cooperative agreement awards supported by

the National Center for Research Resources with co-funding provided

by the National Cancer Institute, the National Heart, Lung, and Blood

Institute, and the National Institute of Diabetes and Digestive and

Kidney Diseases.

 

.

Return to 1996 Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.